About atai Life Sciences

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

We founded atai in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics.

Minimum 15 minutes delayed. Source:

https://www.atai.life/wp-content/uploads/2020/11/model-22b.png

News Releases

atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

November 13, 2024

- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant depression patients around YE’24 - Remain on track...

atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

October 15, 2024

NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srin...

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

September 4, 2024

NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced tha...

Events

SEC Filings

Filing date Form Description
10-Q/A

Amendment to a previously filed 10-Q